STgen Bio (formerly DM Bio) is a CDMO specializing in the development and manufacturing of mammalian cell culture based therapeutic proteins and monoclonal antibodies. STgen Bio developed as a joint venture between Dong-A Socio Holdings and Meiji Seika Pharma, which both have long histories in the pharmaceutical industry of Korea and Japan, respectively. Since its first manufacture in 2015, STgen Bio dedicates itself to matching specific demands of global biotechnology companies with highly qualified experts and state-of-the-art manufacturing facilities.